Pathstone Holdings
CNTX icon

Pathstone Holdings’s Context Therapeutics CNTX Stock Holding History

Pathstone Holdings’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119K Buy
214,875
+104,631
+95% +$212K ﹤0.01% 2279
2026
Q1 		$289K Hold
110,244
– – ﹤0.01% 1990
2025
Q4 		$162K Hold
110,244
– – ﹤0.01% 2133
2025
Q3 		$107K Buy
+110,244
New +$89.4K ﹤0.01% 2267

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Pathstone Holdings's CNTX Position: Q2 2026 in Review

Pathstone Holdings increased its Context Therapeutics (CNTX) stake by 95% in Q2 2026, buying an estimated $212K and bringing the position to 214,875 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #2279.

Pathstone Holdings first reported a position in CNTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $289K in Q1 2026. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Pathstone Holdings held 214,875 shares of Context Therapeutics worth $119K as of Q2 2026.
  • Pathstone Holdings bought 104,631 Context Therapeutics shares in Q2 2026, an estimated $212K.
  • Context Therapeutics made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #2279 holding.
  • Pathstone Holdings first reported a position in Context Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Pathstone Holdings's Context Therapeutics position peaked at $289K in Q1 2026.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.